Egalet announced plans to launch Oxaydo (oxycodone HCl) tablets for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxaydo is formerly known as Oxecta (Pfizer).

Oxaydo, a CII controlled substance, is the first immediate-release oxycodone formulation to deter abuse via snorting. Oxycodone HCl is is a pure opioid agonist and is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. Its principal therapeutic action is analgesia.

RELATED: Study: Abuse, Addiction, Poisoning Diagnoses Decrease with Reformulated Oxycontin

Oxaydo tablets will be available in 5mg and 7.5mg strength tablets in 100-count bottles. It is anticipated to launch in the third quarter of 2015.

For more information call (855) 228-7201 or visit